CoChat

The Roles of Cancer Stem Cells and Therapy Resistance in Colorectal Carcinoma

Open access

The DOI matches its Crossref record; 116 of the 119 references it cites were found in a registry or an index.

Abstract

Cancer stem cells (CSCs) are the main culprits involved in therapy resistance and disease recurrence in colorectal carcinoma (CRC). Results using cell culture, animal models and tissues from patients with CRC suggest the indispensable roles of colorectal CSCs in therapeutic failure. Conventional therapies target proliferating and mature cancer cells, while CSCs are mostly quiescent and poorly differentiated, thereby they can easily survive chemotherapeutic insults. The aberrant activation of Wnt/β-catenin, Notch, Hedgehog, Hippo/YAP (Yes-associated protein) and phosphatidylinositol 3-kinase/protein kinase B facilitates CSCs with excessive self-renewal and therapy resistance property in CRC. CSCs survive the chemo-radiotherapies by escaping therapy mediated DNA damage via altering the cell cycle checkpoints, increasing DNA damage repair capacity and by an efficient scavenging of reactive oxygen species. Furthermore, dysregulations of miRNAs e.g., miR-21, miR-93, miR-203, miR-215, miR-497 etc., modulate the therapeutic sensitivity of colorectal CSCs by regulating growth and survival signalling. In addition, a reversible quiescent G0 state and the re-entering cell cycle capacity of colorectal CSCs can accelerate tumour regeneration after treatment. Moreover, switching to favourable metabolic signatures during a therapeutic regimen will add more complexity in therapeutic outcomes against CSCs. Therapeutic strategies targeting these underlying mechanisms of CSCs’ therapy resistance could provide a promising outcome, however, deep understanding and concerted research are necessary to design novel therapies targeting CSCs. To conclude, the understanding of these mechanisms of CSC in CRC could lead to the improved management of patients with CRC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/cells9061392

Cites

116 of 116 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 The features represent special characteristics, crucial signalling pathways and associated miRNAs of cancer stem cells (CSCs) in causing therapy resistance in colorectal carcinoma.
Figure 1 The features represent special characteristics, crucial signalling pathways and associated miRNAs of cancer stem cells (CSCs) in causing therapy resistance in colorectal carcinoma.CC BY · PubMed Central
Figure 2 Overview of signalling pathways defining colorectal CSC populations. Wnt, Notch, Hedgehog, PI3/AKT and Hippo pathways are implicated to regulate CSC populations, leading to increase in proliferation, invasiveness, and most importantly, resistance to therapies.
Figure 2 Overview of signalling pathways defining colorectal CSC populations. Wnt, Notch, Hedgehog, PI3/AKT and Hippo pathways are implicated to regulate CSC populations, leading to increase in proliferation, invasiveness, and most importantly, resistance to therapies.CC BY · PubMed Central
Figure 3 miRNAs in regulating characteristics of CSCs in colorectal carcinoma (CRC): miRNAs can both inhibit or stimulate the development and characteristics of CSCs, such as the ability of self-renewal, therapy resistance, etc. These changes are through targeting signalling pathways, transcription factors, proteins associated with cell cycle, drug efflux, apoptosis and histone deacetylation, etc.
Figure 3 miRNAs in regulating characteristics of CSCs in colorectal carcinoma (CRC): miRNAs can both inhibit or stimulate the development and characteristics of CSCs, such as the ability of self-renewal, therapy resistance, etc. These changes are through targeting signalling pathways, transcription factors, proteins associated with cell cycle, drug efflux, apoptosis and histone deacetylation, etc.CC BY · PubMed Central
Figure 4 Therapeutic modelling to reduce or inhibit the therapeutic resistance property of CSCs. (i) Inhibition of cell cycle checkpoints, (ii) Inhibition of hyper-activated signalling pathways, (iii) Regulated expression of miRNAs, (iv) Induction of differentiation of CSCs.
Figure 4 Therapeutic modelling to reduce or inhibit the therapeutic resistance property of CSCs. (i) Inhibition of cell cycle checkpoints, (ii) Inhibition of hyper-activated signalling pathways, (iii) Regulated expression of miRNAs, (iv) Induction of differentiation of CSCs.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Cited by

See all 222

Metadata

Authors
Das, P. K., Islam, F., & Lam, A. K.
Affiliations
  • University of Rajshahi (BD)
  • Griffith University (AU)
Corresponding author
  • Islam, Farhadul
  • Lam, Alfred K.
Venue
Cells
Publisher
MDPI AG
Published
2020-06-03
Volume
9
Issue
6
Pages
1392
ISSN
2073-4409 (ISSN-L)
OpenAlex
W3033624893
Cited by
210
References
119
Citations by year
2026: 12 · 2025: 29 · 2024: 42 · 2023: 47 · 2022: 48 · 2021: 27 · 2020: 5
FWCI
3.43
Type
journal article
Language
en
Open access
Locations
  • Cells (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Griffith Research Online (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
Keywords
cancer stem cells, colorectal cancer, treatment resistance, Wnt/β-catenin signaling, Notch signaling, Hedgehog signaling, Hippo/YAP signaling, PI3K/Akt signaling, DNA repair, reactive oxygen species scavenging, cell cycle checkpoints, microRNA, metabolic reprogramming, chemoradiotherapy, self-renewal
MeSH terms
Animals, DNA Damage, Humans, Neoplastic Stem Cells, Colorectal Neoplasms, Signal Transduction, Drug Resistance, Neoplasm, MicroRNAs

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.